These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
607 related articles for article (PubMed ID: 10554037)
21. p53 mutation is infrequent in clear cell carcinoma of the ovary. Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858 [TBL] [Abstract][Full Text] [Related]
22. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer. Ferretti G; Curigliano G; Pastorino U; Cittadini A; Flamini G; Calabrò MG; De Pas T; Orlando L; Mandalà M; Colleoni M; Spaggiari L; Granone PL; Pagliari G; de Braud F; Fazio N; Goldhirsch A Clin Cancer Res; 2000 Jun; 6(6):2393-400. PubMed ID: 10873091 [TBL] [Abstract][Full Text] [Related]
23. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Casey G; Lopez ME; Ramos JC; Plummer SJ; Arboleda MJ; Shaughnessy M; Karlan B; Slamon DJ Oncogene; 1996 Nov; 13(9):1971-81. PubMed ID: 8934544 [TBL] [Abstract][Full Text] [Related]
24. Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma. Koga T; Hashimoto S; Sugio K; Yoshino I; Mojtahedzadeh S; Matsuo Y; Yonemitsu Y; Sugimachi K; Sueishi K Clin Cancer Res; 2001 Jun; 7(6):1730-8. PubMed ID: 11410513 [TBL] [Abstract][Full Text] [Related]
26. Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations. Boldrini L; Gisfredi S; Ursino S; Lucchi M; Mussi A; Basolo F; Pingitore R; Fontanini G Lung Cancer; 2005 Dec; 50(3):309-17. PubMed ID: 16125276 [TBL] [Abstract][Full Text] [Related]
27. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China. Gao H; Wang LD; Zhou Q; Hong JY; Huang TY; Yang CS Cancer Res; 1994 Aug; 54(16):4342-6. PubMed ID: 8044781 [TBL] [Abstract][Full Text] [Related]
28. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Kishimoto Y; Murakami Y; Shiraishi M; Hayashi K; Sekiya T Cancer Res; 1992 Sep; 52(17):4799-804. PubMed ID: 1324794 [TBL] [Abstract][Full Text] [Related]
29. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Mitsudomi T; Steinberg SM; Nau MM; Carbone D; D'Amico D; Bodner S; Oie HK; Linnoila RI; Mulshine JL; Minna JD Oncogene; 1992 Jan; 7(1):171-80. PubMed ID: 1311061 [TBL] [Abstract][Full Text] [Related]
35. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785 [TBL] [Abstract][Full Text] [Related]
36. Mutational spectra of p53 in geographically localized esophageal squamous cell carcinoma groups in China. Cao W; Chen X; Dai H; Wang H; Shen B; Chu D; McAfee T; Zhang ZF Cancer; 2004 Aug; 101(4):834-44. PubMed ID: 15305417 [TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Horio Y; Takahashi T; Kuroishi T; Hibi K; Suyama M; Niimi T; Shimokata K; Yamakawa K; Nakamura Y; Ueda R Cancer Res; 1993 Jan; 53(1):1-4. PubMed ID: 8380124 [TBL] [Abstract][Full Text] [Related]
38. p53 and cyclin D1 as prognostic factors in squamous cell carcinoma of the larynx. Vielba R; Bilbao J; Ispizua A; Zabalza I; Alfaro J; Rezola R; Moreno E; Elorriaga J; Alonso I; Baroja A; de la Hoz C Laryngoscope; 2003 Jan; 113(1):167-72. PubMed ID: 12514403 [TBL] [Abstract][Full Text] [Related]
39. Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs). Garinis GA; Gorgoulis VG; Mariatos G; Zacharatos P; Kotsinas A; Liloglou T; Foukas P; Kanavaros P; Kastrinakis NG; Vassilakopoulos T; Vogiatzi T; Field JK; Kittas C J Pathol; 2001 Jan; 193(1):55-65. PubMed ID: 11169516 [TBL] [Abstract][Full Text] [Related]
40. TP53 mutations do not correlate with locoregional recurrence in stage I tongue carcinomas. Högmo A; Börresen-Dale AL; Blegen H; Lindholm J; Kuylenstierna R; Auer G; Munck-Wikland E Anticancer Res; 1999; 19(4C):3433-8. PubMed ID: 10629631 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]